Electron microscopy of a new variant of congenital dyserythropoietic anaemia type II has yielded several unexpected results. The remarkable features include the relatively high percentage of erythrocytes with peripheral cisternae, the involvement of all bone marrow precursor cells, and the presence of ultrastructural defects in the granulocytes and platelets and on the cell surface of the erythrocytes. Experiments with vinblastine showed that this drug was capable of producing (in vitro) strikingly similar ultrastructural defects in healthy erythrocytes.
This content is only available via PDF.
© 1980 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.